[go: up one dir, main page]

BRPI0409962A - co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente - Google Patents

co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente

Info

Publication number
BRPI0409962A
BRPI0409962A BRPI0409962-1A BRPI0409962A BRPI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A BR PI0409962 A BRPI0409962 A BR PI0409962A
Authority
BR
Brazil
Prior art keywords
excipient
active substance
formulation
pharmaceutical
particulate
Prior art date
Application number
BRPI0409962-1A
Other languages
English (en)
Inventor
Stephen Ernest Walker
Caroline Sophie German
Linda Sharon Daintree
Original Assignee
Nektar Therapeutics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0310636A external-priority patent/GB0310636D0/en
Application filed by Nektar Therapeutics Uk Ltd filed Critical Nektar Therapeutics Uk Ltd
Publication of BRPI0409962A publication Critical patent/BRPI0409962A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"CO-FORMULAçãO PARTICULADA DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE, COMPOSIçãO FARMACêUTICA OU NUTRICêUTRICA, PRODUTO FARMACêUTICO OU NUTRICêUTICO, MéTODO PARA PREPARAR UMA CO-FORMULAçãO PARTICULADA DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE, E, USO DE UMA SUBSTáNCIA ATIVA E UM EXCIPIENTE". Uma co-formulação particulada, cada partícula compreendendo um núcleo de uma substância ativa envolvido por um revestimento do excipiente, as partículas tendo um diâmetro de partícula médio em volume de (10) <109>m ou menos, a qual em administração oral libera a substância ativa a uma taxa tal que o tempo (T~ max~) levado para alcançar a concentração ativa máxima da substância ativa na corrente sanguinea do paciente é uma hora ou menos. A co-formulação pode ser produzida usando um processo de formação de partícula de SFC Nektar<32>.
BRPI0409962-1A 2003-05-08 2004-05-05 co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente BRPI0409962A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310636A GB0310636D0 (en) 2003-05-08 2003-05-08 Particulate materials
GB0329964A GB0329964D0 (en) 2003-05-08 2003-12-24 Particulate materials
PCT/GB2004/001935 WO2004098561A2 (en) 2003-05-08 2004-05-05 Particulate materials

Publications (1)

Publication Number Publication Date
BRPI0409962A true BRPI0409962A (pt) 2006-04-25

Family

ID=32510407

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409962-1A BRPI0409962A (pt) 2003-05-08 2004-05-05 co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente

Country Status (10)

Country Link
US (1) US7354601B2 (pt)
EP (1) EP1624862B1 (pt)
JP (1) JP2006525303A (pt)
KR (1) KR20060015587A (pt)
AU (1) AU2004237131B2 (pt)
BR (1) BRPI0409962A (pt)
CA (1) CA2524773C (pt)
GB (1) GB2401547B (pt)
MX (1) MXPA05011343A (pt)
WO (1) WO2004098561A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974595B1 (en) 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
US7687542B2 (en) 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AU2004268929A1 (en) * 2003-05-02 2005-03-10 3M Innovative Properties Company Crossflow filtration system with quick dry change elements
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
CN101277682B (zh) * 2005-07-28 2015-07-29 Isp投资有限公司 无定形依发韦仑及其生产
JP2007176869A (ja) * 2005-12-28 2007-07-12 Univ Meijo 難溶性薬物含有微細粒子
US7939561B2 (en) 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens
US7700125B2 (en) 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
ES2472699T3 (es) 2006-10-11 2014-07-02 Crititech, Inc. Aparato para precipitación de partículas pequeñas de medicamento en recipientes de uso
US20080131504A1 (en) * 2006-12-01 2008-06-05 Mission Pharmacal Co. Short Term Slow Release Drug Delivery System
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
CN101677954A (zh) 2007-02-11 2010-03-24 Map药物公司 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
SG195015A1 (en) * 2011-05-20 2013-12-30 Aventis Pharma Inc Pharmaceutical composition comprising fexofenadine
JP2021028305A (ja) * 2019-08-09 2021-02-25 株式会社リコー 粒子、医薬組成物、及び粒子の製造方法
CN115321908B (zh) * 2022-08-10 2023-05-16 河南金诺混凝土有限公司 基于高品质机制砂的高性能混凝土及其制备方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE418247B (sv) 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4582731A (en) 1983-09-01 1986-04-15 Battelle Memorial Institute Supercritical fluid molecular spray film deposition and powder formation
US4514574A (en) 1984-01-09 1985-04-30 The Dow Chemical Company Process for separating isomeric mixtures
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4737384A (en) 1985-11-01 1988-04-12 Allied Corporation Deposition of thin films using supercritical fluids
US5219575A (en) 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0321607B1 (en) 1987-12-21 1993-09-22 Union Carbide Corporation Supercritical fluids as diluents in liquid spray application of coatings
DE3744329A1 (de) 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
JPH01176437A (ja) 1987-12-29 1989-07-12 Ono Pharmaceut Co Ltd 有機物質の微粒化方法
US5066522A (en) 1988-07-14 1991-11-19 Union Carbide Chemicals And Plastics Technology Corporation Supercritical fluids as diluents in liquid spray applications of adhesives
HU209603B (en) 1988-10-05 1994-09-28 Upjohn Co Process for production of solid powders in finalydivided microcristallin form
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5232707A (en) 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5106659A (en) 1989-10-04 1992-04-21 Nordson Corporation Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas
US4970093A (en) 1990-04-12 1990-11-13 University Of Colorado Foundation Chemical deposition methods using supercritical fluid solutions
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
CA2044706C (en) 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
US5037912A (en) 1990-07-26 1991-08-06 The Goodyear Tire & Rubber Company Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
DE4118230A1 (de) 1990-12-20 1992-06-25 Bayer Ag Verfahren zur isolierung von polymeren aus ihren loesungsmitteln mit kohlendioxid-haltigen fluessigkeiten
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
DE4117751A1 (de) 1991-05-30 1992-12-03 Bayer Ag Verfahren zur isolierung von polycarbonaten
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5196575A (en) 1992-02-19 1993-03-23 Hoechst Celanese Corp. Supercritical separation of isomers of functional organic compounds at moderate conditions
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
BR9307346A (pt) 1992-11-02 1999-06-01 Ferro Corp Processo para preparação de materiais de revestimento
DE59308043D1 (de) 1993-02-24 1998-02-26 Sulzer Chemtech Ag Reinigung von salzbeladenem Abwasser durch Nassoxidation bei superkritischen Bedingungen
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
CN1139390A (zh) 1993-11-08 1997-01-01 吉莱特公司 使用超临界流体形成颗粒的方法，由该方法形成的气溶胶颗粒，及含有气溶胶颗粒的防汗剂
IT1265473B1 (it) 1993-12-30 1996-11-22 Otefal Srl Procedimento per la produzione di polveri a granulometria controllata e prodotto in polvere cosi' ottenuto
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
SI9400079B (sl) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Postopek in naprava za pridobivanje in frakcioniranje majhnih delcev iz raztopin nasičenih s plinom
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5560543A (en) 1994-09-19 1996-10-01 Board Of Regents, The University Of Texas System Heat-resistant broad-bandwidth liquid droplet generators
MX9504934A (es) 1994-12-12 1997-01-31 Morton Int Inc Revestimientos en polvo de pelicula delgada lisa.
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
ATE386506T1 (de) 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
FR2753639B1 (fr) 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9800936D0 (en) 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9804001D0 (sv) 1998-11-23 1998-11-23 Astra Ab New process
CA2351720C (en) 1998-11-25 2006-11-21 Cima Labs Inc. Taste masking rapid release coating system
SE9901667D0 (sv) 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20030215513A1 (en) * 2002-02-21 2003-11-20 Peter Fyhr Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
WO2003074029A1 (en) 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
MXPA04008737A (es) 2002-03-08 2005-07-13 M S Ind Swift Ltd Complejos que se disuelven rapidamente, comprensibles directamente, insipidos, y formulaciones farmaceuticas de los mismos.
WO2004098561A2 (en) 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials

Also Published As

Publication number Publication date
WO2004098561A3 (en) 2005-09-01
EP1624862A2 (en) 2006-02-15
JP2006525303A (ja) 2006-11-09
GB2401547A (en) 2004-11-17
US7354601B2 (en) 2008-04-08
GB0409973D0 (en) 2004-06-09
CA2524773A1 (en) 2004-11-18
GB2401547B (en) 2005-07-20
US20050170000A1 (en) 2005-08-04
MXPA05011343A (es) 2005-12-12
WO2004098561A2 (en) 2004-11-18
KR20060015587A (ko) 2006-02-17
EP1624862B1 (en) 2014-12-31
CA2524773C (en) 2014-04-08
AU2004237131B2 (en) 2009-09-10
AU2004237131A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
BRPI0409962A (pt) co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente
Venook et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
ATE278387T1 (de) Verfahren zur herstellung von pharmazeutischen nanosuspensionen
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
FI20002215A0 (fi) Yhdistelmäpartikkelit
HUP9802828A2 (hu) Belélegezhető vivőanyag szabályozott hatóanyag-leadású gyógyszerkészítményekhez
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
FI971880A0 (fi) Helposti sulavan kantajan sisältävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
DE59209244D1 (de) Inhalationspulver und verfahren zu ihrer herstellung
HUP0401224A2 (hu) Eljárás gyógyászati készítmények előállítására lágyzselatin-összetételekkel való felhasználás céljára
ATE196422T1 (de) Schnellauflösliche pharmazeutische dosierungsformen und verfahren zu ihrer herstellung
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
BR0211198A (pt) Composições farmacêuticas e seu uso
AR034640A1 (es) Composicion de liberacion sostenida y proceso para producirla
JP6042696B2 (ja) 防已含有組成物
EP1393734A4 (en) DRUGS FOR INTESTINAL DISEASES
DK1561460T3 (da) Nanopartikler til indgivelse af aktive ingredienser, fremgangsmåde til fremstilling af nævnte partikler og komposition, som omfatter det samme
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
EA200500387A1 (ru) Композиции для ингаляции с высоким содержанием лекарственных веществ
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso
BR0307319A (pt) Forma de dosagem oral para liberação controlada de droga
JP2014214141A (ja) 防已含有組成物

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]